Display options
Share it on

Int J Clin Exp Pathol. 2021 Mar 01;14(3):338-347. eCollection 2021.

Bone metastasis: evaluation of 1100 patients with breast cancer.

International journal of clinical and experimental pathology

Koray Başdelioğlu

Affiliations

  1. Department of Orthopaedic and Traumatology, Istanbul Oncology Hospital Istanbul, Turkey.

PMID: 33786150 PMCID: PMC7994145

Abstract

The aim of this study is to determine the relationship between the demographics and the clinical characteristics of breast cancer (BC) patients with bone metastasis (BM). The study included 1100 BC patients, of whom 174 had BMs and 926 had no BMs. Immunohistochemical methods were employed to understand estrogen receptor (ER)/progesterone receptor (PgR) receptor levels, Ki-67 protein levels and human epidermal growth factor receptor 2 (HER2) expression levels. Data were collected based on the hospital records of these patients, and ultrasonography or magnetic resonance imaging (MRI) results were employed for tumor localization. Positron emission tomography (PET)-computed tomography (CT) data were employed for the BM evaluation. The mean age (P = 0.067) and tumor diameter (P = 0.022) of BC cases who showed BM were significantly different from those who did not show BM. In addition, a significant relationship between the tumor diameter (P = 0.001) and axillary lymph node (ALN) number (P = 0.000) and BM was observed. The percentages of ER and PgR (r = 0.639; P = 0.000) were positively correlated, while the percentage of ER and Ki-67 protein levels (r = -0.505; P = 0.000) were negatively correlated. However, these correlations were not significant between the groups. The tumor diameter and positive ALNs may have an important role in BM of BC. There was no significant effect of ER/PgR receptor levels, Ki-67 protein levels, or HER2 expression levels in BMs of BC.

IJCEP Copyright © 2021.

Keywords: Breast cancer; ER; HER2; Ki-67; PgR; bone metastasis

Conflict of interest statement

None.

References

  1. J Immunol Methods. 2018 Jan;452:46-52 - PubMed
  2. Breast Cancer Res. 2002;4(5):197-201 - PubMed
  3. Support Care Cancer. 2016 Sep;24(9):4035-43 - PubMed
  4. Breast Cancer Res Treat. 2011 Oct;129(3):659-74 - PubMed
  5. Nucl Med Rev Cent East Eur. 2013;16(2):66-9 - PubMed
  6. Sci Rep. 2017 Aug 23;7(1):9254 - PubMed
  7. Int J Clin Oncol. 2014 Oct;19(5):852-62 - PubMed
  8. Ann Oncol. 2011 Aug;22(8):1736-47 - PubMed
  9. Cancer Biol Ther. 2008 Jan;7(1):3-9 - PubMed
  10. Int J Cancer. 2019 Apr 15;144(8):1941-1953 - PubMed
  11. Breast Cancer Res Treat. 2016 Apr;156(3):587-595 - PubMed
  12. Cancer. 1997 Oct 15;80(8 Suppl):1588-94 - PubMed
  13. Cancer Res. 1989 Jun 1;49(11):2999-3006 - PubMed
  14. Int J Clin Exp Pathol. 2009 Nov 10;3(2):139-46 - PubMed
  15. BMC Cancer. 2016 May 12;16:307 - PubMed
  16. Cancer Res. 2007 May 1;67(9):4190-8 - PubMed
  17. NPJ Breast Cancer. 2017 Oct 2;3:39 - PubMed
  18. Eur J Cancer. 2014 Jul;50(10):1697-1705 - PubMed
  19. Pharmacol Res. 2014 Jan;79:34-74 - PubMed
  20. Cancer. 1981 Jun 15;47(12):2923-7 - PubMed
  21. JAMA. 1977 Jun 6;237(23):2504-6 - PubMed
  22. Clin Transl Radiat Oncol. 2017 Oct 24;7:20-27 - PubMed
  23. J Clin Oncol. 2000 Dec 1;18(23):3925-35 - PubMed
  24. J Clin Oncol. 2010 Jul 10;28(20):3271-7 - PubMed
  25. J Clin Invest. 2018 Apr 2;128(4):1355-1370 - PubMed
  26. Nat Commun. 2017 Apr 20;8:14944 - PubMed
  27. Sci Rep. 2017 Sep 12;7(1):11325 - PubMed
  28. Nature. 2016 Dec 22;540(7634):552-558 - PubMed
  29. Lancet Oncol. 2013 Sep;14(10):1009-19 - PubMed
  30. Cell. 2013 Aug 29;154(5):957-959 - PubMed
  31. Pathol Res Pract. 1989 Dec;185(6):856-9 - PubMed
  32. Br J Cancer. 1987 Jan;55(1):61-6 - PubMed
  33. Virchows Arch. 2017 Mar;470(3):275-283 - PubMed

Publication Types